Abstract:The blood-brain barrier (BBB) is a formidable gatekeeper toward exogenous substances, playing an important role in brain homeostasis and maintaining a healthy microenvironment for complex neuronal activities. However, it also greatly hinders drug permeability into the brain and limits the management of brain diseases. The development of new drugs that show improved transport across the BBB represents a promising strategy for Alzheimer's disease (AD) intervention. Whereas, previous study of receptor-mediated endogenous BBB transport systems has focused on a strategy of using transferrin to facilitate brain drug delivery system, a system that still suffers from limitations including synthesis procedure, stability and immunological response. In the present study, we synthetised sialic acid (SA)-modified selenium (Se) nanoparticles conjugated with an alternative peptide-B6 peptide (B6-SA-SeNP5, a synthetic selenoprotein analogue), which shows high permeability across the BBB and has the potential to serve as a novel nanomedicine for disease modification in AD. Laser-scanning confocal microscopy, flow cytometry analysis and inductively coupled plasma-atomic emission spectroscopy ICP-AES revealed high cellular uptake of B6-SA-SeNP5 by cerebral endothelial cells (bEnd3). The transport efficiency of B6-SA-SeNP5 was evaluated in a Transwell experiment based on in vitro BBB model. It provided direct evidence for B6-SA-SeNP5 crossing the BBB and being absorbed by PC12 cells. Moreover, inhibitory effects of B6-SA-SeNPs on amyloid-beta peptide (A beta) fibrillation could be demonstrated in PC12 cells and bEnd3 cells. B6-SA-SeNP5 could not only effectively inhibit A beta aggregation but could disaggregate preformed A beta fibrils into non-toxic amorphous oligomers. These results suggested that B6-SA-SeNP5 may provide a promising platform, particularly for the application of nanoparticles in the treatment of brain diseases.Statement of SignificanceAlzheimer's disease (AD) is the world's most common form of dementia characterized by intracellular neurofibrillary tangles in the brain. Over the past decades, the blood-brain barrier (BBB) limits access of therapeutic or diagnostic agents into the brain, which greatly hinders the development of new drugs for treating AD. In this work, we evaluated the efficiency of B6-SA-SeNP5 across BBB and investigated the interactions between B6-SA-SeNP5 and amyloid-beta peptide (A beta). We confirm that B6-SA-SeNP5 could provide a promising platform because of its high brain delivery efficiency, anti-amyloid properties and anti-oxidant properties, which may serve as a novel nanomedicine for the application in the treatment of brain diseases. (C) 2015 Acta Materialia Inc. Published by Elsevier Ltd. All rights reserved.

Intranasal administration of silibinin-loaded pullulan acetate nanocarriers: A pH-responsive approach for brain targeting in Alzheimer's disease

Development of silibinin-loaded nanostructured lipid carriers for Alzheimer's disease induced by amyloid beta in Wistar rats

Intranasal Piperine-Loaded Chitosan Nanoparticles as Brain-Targeted Therapy in Alzheimer's Disease: Optimization, Biological Efficacy, and Potential Toxicity

Formulation and Characterization of Silibinin Entrapped Nano-Liquid Crystals for Activity against Aβ1-42 Neurotoxicity in In-Vivo Model

Brain-targeted Tet-1 peptide-PLGA nanoparticles for berberine delivery against STZ-induced Alzheimer's disease in a rat model: Alleviation of hippocampal synaptic dysfunction, Tau pathology and amyloidogenesis

Lactoferrin-modified PEG-co-PCL Nanoparticles for Enhanced Brain Delivery of NAP Peptide Following Intranasal Administration

Cell-penetrating Peptide-Modified PLGA Nanoparticles for Enhanced Nose-to-brain Macromolecular Delivery

Intranasal Nanoparticles of Basic Fibroblast Growth Factor for Brain Delivery to Treat Alzheimer'S Disease

Preparation, physicochemical characterization, ex vivo , and in vivo evaluations of asiatic acid-loaded solid lipid nanoparticles formulated with natural waxes for nose-to-brain delivery

Microfluidic Synthesis of Ultrasmall Chitosan/Graphene Quantum Dots Particles for Intranasal Delivery in Alzheimer's Disease Treatment

Sialic Acid (Sa)-Modified Selenium Nanoparticles Coated with a High Blood–brain Barrier Permeability Peptide-B6 Peptide for Potential Use in Alzheimer’s Disease

Nanocarriers-mediated nose-to-brain drug delivery: A novel approach for the management of Alzheimer's Disease

Nasal timosaponin BII dually sensitive in situ hydrogels for the prevention of Alzheimer's disease induced by lipopolysaccharides

Customized Intranasal Hydrogel Delivering Methylene Blue Ameliorates Cognitive Dysfunction Against Alzheimer's Disease.

QbD-based rivastigmine tartrate-loaded solid lipid nanoparticles for enhanced intranasal delivery to the brain for Alzheimer's therapeutics

Intranasal H102 Peptide-Loaded Liposomes for Brain Delivery to Treat Alzheimer’s Disease

Brain Delivery of NAP with PEG-PLGA Nanoparticles Modified with Phage Display Peptides

Intranasal Delivery of BACE1 siRNA and Rapamycin by Dual Targets Modified Nanoparticles for Alzheimer's Disease Therapy.

Surface-modified liposomal in-situ nasal gel enhances brain targeting of berberine hydrochloride for Alzheimer's therapy: optimization and in vivo studies

Microneedle-mediated nose-to-brain drug delivery for improved Alzheimer's disease treatment

Nanostructured Lipid Carriers of Donepezil Hydrochloride for the Treatment of Alzheimer’s Disease